Tandem Diabetes Care Inc (TNDM)
40.27
+0.45
(+1.13%)
USD |
NASDAQ |
Jul 05, 14:10
Tandem Diabetes Care SG&A Expense (Annual): 352.50M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 352.50M |
| December 31, 2022 | 335.68M |
| December 31, 2021 | 261.51M |
| December 31, 2020 | 204.90M |
| December 31, 2019 | 165.74M |
| December 31, 2018 | 105.23M |
| December 31, 2017 | 86.38M |
| Date | Value |
|---|---|
| December 31, 2016 | 82.83M |
| December 31, 2015 | 78.62M |
| December 31, 2014 | 75.12M |
| December 31, 2013 | 44.52M |
| December 31, 2012 | 22.69M |
| December 31, 2011 | 15.95M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
165.74M
Minimum
2019
352.50M
Maximum
2023
264.07M
Average
261.51M
Median
2021
SG&A Expense (Annual) Benchmarks
| Insulet Corp | 734.90M |
| Abbott Laboratories | 10.95B |
| ICU Medical Inc | 606.69M |
| Twist Bioscience Corp | 189.74M |
| Perspective Therapeutics Inc | 21.06M |